Stoke Therapeutics price target lowered to $35 from $47 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Stoke Therapeutics (STOK) to $35 from $47 and keeps a Buy rating on the shares after Stoke announced that the Phase 3 EMPEROR trial might begin around Q2. The EMPEROR trial is “designed for success, with robust methodology and global regulatory alignment supporting its credibility,” says the analyst, who is lowering the firm’s multiples and increasing discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk, leading to the firm’s reduced price target on Stoke shares.